-DOCSTART- -X- O
Ethyl -X- _ B-Intervention
pyruvate -X- _ I-Intervention
( -X- _ I-Intervention
EP -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
simple -X- _ O
derivative -X- _ O
of -X- _ O
pyruvic -X- _ O
acid -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
an -X- _ O
important -X- _ O
endogenous -X- _ O
metabolite -X- _ O
that -X- _ O
can -X- _ O
scavenge -X- _ O
reactive -X- _ O
oxygen -X- _ O
species -X- _ O
( -X- _ O
ROS -X- _ O
) -X- _ O
. -X- _ O
Treatment -X- _ O
with -X- _ O
EP -X- _ B-Outcome
is -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
ameliorate -X- _ I-Outcome
systemic -X- _ I-Outcome
inflammation -X- _ I-Outcome
and -X- _ I-Outcome
multiple -X- _ I-Outcome
organ -X- _ I-Outcome
dysfunctions -X- _ I-Outcome
in -X- _ I-Outcome
multiple -X- _ I-Outcome
animal -X- _ I-Outcome
models -X- _ I-Outcome
, -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
acute -X- _ I-Outcome
pancreatitis -X- _ I-Outcome
, -X- _ I-Outcome
alcoholic -X- _ I-Outcome
liver -X- _ I-Outcome
injury -X- _ I-Outcome
, -X- _ I-Outcome
acute -X- _ I-Outcome
respiratory -X- _ I-Outcome
distress -X- _ I-Outcome
syndrome -X- _ I-Outcome
( -X- _ I-Outcome
ARDS -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
acute -X- _ I-Outcome
viral -X- _ I-Outcome
myocarditis -X- _ I-Outcome
, -X- _ I-Outcome
acute -X- _ I-Outcome
kidney -X- _ I-Outcome
injury -X- _ I-Outcome
and -X- _ I-Outcome
sepsis. -X- _ I-Outcome
Recent -X- _ O
studies -X- _ O
have -X- _ O
demonstrated -X- _ O
that -X- _ O
prolonged -X- _ O
treatment -X- _ O
with -X- _ O
EP -X- _ O
can -X- _ O
ameliorate -X- _ O
experimental -X- _ O
ulcerative -X- _ O
colitis -X- _ O
and -X- _ O
slow -X- _ O
multiple -X- _ O
tumor -X- _ O
growth. -X- _ O
It -X- _ O
has -X- _ O
become -X- _ O
evident -X- _ O
that -X- _ O
EP -X- _ O
has -X- _ O
pharmacological -X- _ O
anti-inflammatory -X- _ O
effect -X- _ O
to -X- _ O
inhibit -X- _ O
multiple -X- _ O
early -X- _ O
inflammatory -X- _ O
cytokines -X- _ O
and -X- _ O
the -X- _ O
late -X- _ O
inflammatory -X- _ O
cytokine -X- _ O
HMGB1 -X- _ O
release -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
anti-tumor -X- _ O
activity -X- _ O
is -X- _ O
likely -X- _ O
associated -X- _ O
with -X- _ O
its -X- _ O
anti-inflammatory -X- _ O
effect. -X- _ O
EP -X- _ O
has -X- _ O
been -X- _ O
tested -X- _ O
in -X- _ O
human -X- _ O
volunteers -X- _ O
and -X- _ O
in -X- _ O
a -X- _ O
clinical -X- _ O
trial -X- _ O
of -X- _ O
patients -X- _ O
undergoing -X- _ O
cardiac -X- _ O
surgery -X- _ O
in -X- _ O
USA -X- _ O
and -X- _ O
shown -X- _ O
to -X- _ O
be -X- _ O
safe -X- _ O
at -X- _ O
clinical -X- _ O
relevant -X- _ O
doses -X- _ O
, -X- _ O
even -X- _ O
though -X- _ O
EP -X- _ O
fails -X- _ O
to -X- _ O
improve -X- _ O
outcome -X- _ O
of -X- _ O
the -X- _ O
heart -X- _ O
surgery -X- _ O
, -X- _ O
EP -X- _ O
is -X- _ O
still -X- _ O
a -X- _ O
promising -X- _ O
agent -X- _ O
to -X- _ O
treat -X- _ O
patients -X- _ O
with -X- _ O
multiple -X- _ O
inflammatory -X- _ O
organ -X- _ O
injuries -X- _ O
and -X- _ O
the -X- _ O
other -X- _ O
clinical -X- _ O
trials -X- _ O
are -X- _ O
on -X- _ O
the -X- _ O
way. -X- _ O
This -X- _ O
review -X- _ O
focuses -X- _ O
on -X- _ O
how -X- _ O
EP -X- _ O
is -X- _ O
able -X- _ O
to -X- _ O
ameliorate -X- _ O
multiple -X- _ B-Patient
organ -X- _ I-Patient
injuries -X- _ I-Patient
and -X- _ O
summarize -X- _ O
recently -X- _ O
published -X- _ O
EP -X- _ O
investigations. -X- _ O
[ -X- _ O
Figure -X- _ O
: -X- _ O
see -X- _ O
text -X- _ O
] -X- _ O

